Home › Funds › Soleus Capital Management, L.P. › RCUS
Soleus Capital Management, L.P. position in RCUS
ARCUS BIOSCIENCES INC · Health Care
Soleus Capital Management, L.P. reported holding 862,000 shares of RCUS (ARCUS BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$22.3M, representing 0.79% of its reported portfolio and ranking #28 among its reported holdings. Soleus Capital Management, L.P. has disclosed RCUS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Soleus Capital Management, L.P.'s RCUS position evolved
Soleus Capital Management, L.P. first disclosed a stake in RCUS in Q4 2025 at 711,983 shares (US$17.0M). The position peaked in Q2 2026 at 1,168,738 shares, worth US$36.0M. Across 4 filings, Soleus Capital Management, L.P. increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 862,000 shares valued at US$22.3M — a reduction of -306,738 shares quarter over quarter.. Notable position changes include a 37% trim in Q1 2026 (shares rose 43% over the following quarter), a 159% increase in Q2 2026 (shares fell 16% over the following quarter), a 26% trim in Q3 2026 (shares fell 35% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 711.98K | $16.97M | New |
| Q1 2026 | 451.98K | $9.76M | Reduce |
| Q2 2026 | 1.17M | $36.03M | Add |
| Q3 2026 | 862.00K | $22.27M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RCUS and 13F data
RCUS (ARCUS BIOSCIENCES INC) is a Health Care company. 41 other funds we track also report a position in RCUS — the largest reported positions include GILEAD SCIENCES, INC. (US$811.7M), Siren, L.L.C. (US$62.5M), SAMLYN CAPITAL, LLC (US$36.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RCUS
- GILEAD SCIENCES, INC. 31.42M sh · $811.70M · Q3 2026
- Siren, L.L.C. 2.42M sh · $62.52M · Q3 2026
- SAMLYN CAPITAL, LLC 1.39M sh · $36.03M · Q3 2026
- Vestal Point Capital, LP 1.30M sh · $33.58M · Q3 2026
- BAKER BROS. ADVISORS LP 844.82K sh · $21.82M · Q3 2026
- Ikarian Capital, LLC 734.56K sh · $18.97M · Q3 2026
- Parkman Healthcare Partners LLC 675.52K sh · $17.45M · Q3 2026
- Sofinnova Investments, Inc. 626.18K sh · $16.17M · Q3 2026
- First Turn Management, LLC 577.69K sh · $14.92M · Q3 2026
- Logos Global Management LP 500.00K sh · $12.91M · Q3 2026
More on Soleus Capital Management, L.P.
FAQ
How long has Soleus Capital Management, L.P. held RCUS?
Soleus Capital Management, L.P. has disclosed RCUS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Soleus Capital Management, L.P.'s current position in RCUS?
As of Q3 2026, Soleus Capital Management, L.P. holds 862.00K shares of RCUS (ARCUS BIOSCIENCES INC), valued at $22.27M, representing 0.79% of its reported portfolio and ranking #28.
Has Soleus Capital Management, L.P. been buying or selling RCUS?
In the latest 13F filing (Q3 2026), Soleus Capital Management, L.P. reduced its position in RCUS. The position peaked in Q2 2026 at 1.17M shares.
Which other funds hold RCUS?
Other major institutional holders of RCUS include GILEAD SCIENCES, INC., Siren, L.L.C., SAMLYN CAPITAL, LLC, among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.